Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)

Recruiting now

Conditions studied: Pancreatic Cancer, Metastasis, Epigenetic

In brief

This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.

Key facts

Study ID

NCT06945978

Run by

Benedito Mauro Rossi

People needed

60

Starts

2025-01-21

Expected to finish

2027-12-01

Last updated by the study team

2025-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with metastatic PDAC;
• Patients who will start treatment with FOLFIRINOX;
• 18 years or older;
• Who agree to participate in the study by signing the Informed Consent Form;

You may not qualify if…

• Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment;
• Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;

Where it is running

• A Beneficência Portuguesa de São Paulo — São Paulo, São Paulo, Brazil (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.